You are here

Article Text

Article menu
Download PDFPDF
Electronic letters
Reproductive counselling for women with myotonic dystrophy
  1. A C Magee1,
  2. A E Hughes2,
  3. A Kidd3,*,
  4. A Lopez de Munain4,
  5. A M Cobo4,
  6. K Kelly3,
  7. J Dean3,
  8. N C Nevin1,2
  1. 1Regional Genetics Service, A Floor, Belfast City Hospital Trust, Lisburn Road, Belfast BT9 7AB, Northern Ireland
  2. 2Department of Medical Genetics, The Queen's University of Belfast, Lisburn Road, Belfast BT9 7AB, Northern Ireland
  3. 3Department of Medical Genetics, Medical School, Foresterhill, Aberdeen AB25 2ZD, UK
  4. 4Neurology and Clinical Epidemiology Departments, Hospital Ntra Sra Aranzazu, San Sebastian, Basque Country, Spain
  1. Correspondence to:
 Dr A Magee, Regional Genetics Service, A Floor, Belfast City Hospital Trust, Lisburn Road, Belfast BT9 7AB, Northern Ireland, 
 Alex.Magee{at}bch.n-i.nhs.uk

https://doi.org/10.1136/jmg.39.3.e15

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Myotonic dystrophy type 1 is the commonest neuromuscular disease affecting adults. It is inherited in an autosomal dominant manner, and is linked to a dynamic expansion of a CTG triplet repeat localised to chromosome 19q13.3. The phenotype can be divided into four main groups: mild, juvenile, classical, and congenital. The most severe form of the condition is observed in congenitally affected infants usually born to classically affected mothers. Recently, the nomenclature has been revised and myotonic dystrophy is referred to as DM1.1

    Congenital myotonic dystrophy (CDM) was first described in 19602 and is the most severe phenotypic expression of DM1. It represents the final stage in the typical three generation anticipation cascade observed in this condition.3 The symptoms may present late in pregnancy with reduced fetal movements, polyhydramnios, or hydrops fetalis.4–6 Often the birth of a severely affected child identifies an extensive DM1 pedigree. The reasons for the almost exclusive maternal transmission of CDM are not clearly understood. There are no particular clinical features in the mothers of CDM children to account for this, but, from earlier studies, all the women exhibited clinical myotonia7 and CDM cases were confined to the offspring of clinically affected women.8 Koch et al9 found that only women with multisystem signs of DM1 at the time of pregnancy and delivery were likely to have congenitally affected offspring and that the chance of having a more severely affected child increased with maternal disease severity. These observations have been given support by more recent molecular studies; infants …

    View Full Text

    Footnotes

    • ↵* Present address: Central Regional Genetic Service, Wellington Hospital, Wellington South, New Zealand